Study consistent with trial results for dabigatran and warfarin in atrial fibrillation

November 13, 2017, Kaiser Permanente

A study of two medications that can reduce risk of ischemic stroke in people with atrial fibrillation showed that outcomes in typical patients with atrial fibrillation align well with those seen in clinical trials. The findings were published on Nov. 14 in Annals of Internal Medicine.

This research, led by Alan Go, MD, director of the Comprehensive Clinical Research Unit within the Kaiser Permanente Division of Research, marks the first major study to examine outcomes of therapies for atrial fibrillation from the U.S. Food and Drug Administration Sentinel Initiative, a national multi-institution network to monitor the safety of new medical products after they reach the market.

Atrial fibrillation is an irregular heart rhythm that increases risk. To reduce this risk, often receive treatment with the blood thinner warfarin, which has been in use since the 1950s, or a newer alternative such as , approved by FDA in late 2010.

The analysis showed that both medications were associated with similar rates of ischemic stroke and overall bleeding. However, people taking dabigatran were less likely to experience bleeding in the brain, which can be dangerous or deadly. These findings were consistent with the results of prior clinical trials that compared the two drugs.

"Our study provides reassurance that stroke-related outcomes seen with dabigatran in selected trial participants translate into usual clinical care for patients with atrial fibrillation," Dr. Go said. "Importantly, while risks of ischemic stroke were similar for dabigatran and warfarin, dabigatran was safer from the standpoint of a lower risk of brain bleeds."

The study also addressed rates associated with each drug, but the results were inconclusive. Patients on dabigatran were more likely to experience a heart attack than patients on warfarin, but the statistical strength and consistency of this finding was unclear.

"The jury is still out," Dr. Go said. "We need more research to rule out the possibility that there might be a higher risk of heart attack with dabigatran in certain patients, such as those who are older and men."

National collaboration

The analysis incorporated data from 50,578 adults aged 21 and older with atrial . Half started dabigatran and half started warfarin between November 2010 and May 2014. To ensure a fair comparison, patients taking dabigatran versus warfarin were statistically matched according to similar demographics, use of additional medications, and many other characteristics.

Patient data was contributed by eight Sentinel collaborators: Kaiser Permanente Northern California, Kaiser Permanente Washington, Aetna, Harvard Pilgrim Health Care Institute, HealthCore, Inc., HealthPartners Institute, Humana Comprehensive Health Insights, Inc., and Optum: Optum Epidemiology.

"The Sentinel program enabled us to look at adults of all ages—not just older patients—who received care across a variety of settings," said senior author Joshua Gagne, PharmD, ScD, of Harvard Medical School. "Ours isn't the first study to address this question outside of , but it is the most wide-ranging and nationally representative."

Future research should examine which types of patients benefit most from which stroke-prevention strategies, Dr. Go said. Indeed, the new study mirrored prior clinical trial results showing higher rates of gastrointestinal bleeding with dabigatran in older patients and those with kidney disease, emphasizing that warfarin is likely still a better choice for some.

Dr. Go's research is now looking at how different patient characteristics might affect ideal treatment choice to optimize outcomes for .

Explore further: When two is better than three: Dual antithrombotic therapy cuts bleeding risk

Related Stories

When two is better than three: Dual antithrombotic therapy cuts bleeding risk

August 28, 2017
Using just two anticlotting medicines for patients who have atrial fibrillation and have had a stent placed in a heart artery is safer than using the current standard treatment of three medications, according to a new study ...

Lower inpatient costs for dabigatran, rivaroxaban in A-fib

January 17, 2017
(HealthDay)—For patients with newly diagnosed atrial fibrillation (AF), inpatient costs are lower with dabigatran and rivaroxaban than with warfarin, according to a letter published online in the Jan. 24 issue of the Journal ...

How safe and effective are new drugs for stroke prevention?

October 3, 2016
For decades, warfarin was the only oral blood thinner available to reduce the risk of stroke for patients with atrial fibrillation. Warfarin use is cumbersome, because it requires ongoing blood test to monitor the effect ...

Risk of hemorrhage with statins and stroke prevention drug combination

November 21, 2016
Two commonly prescribed statins appear to be associated with a higher risk of bleeding than others when combined with dabigatran, a drug often used for preventing strokes in patients with atrial fibrillation, according to ...

Use of novel oral anticoagulants increasing in A-fib

June 15, 2015
(HealthDay)—For patients with atrial fibrillation hospitalized with stroke or transient ischemic attack, use of novel oral anticoagulants (NOACs) has increased over time, according to a study published online June 9 in ...

Lower risk of gastrointestinal bleeding for apixaban

April 10, 2017
(HealthDay)—For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, ...

Recommended for you

New cellular pathway helps explain how inflammation leads to artery disease

June 21, 2018
Investigators have identified a new cellular pathway that may help explain how arterial inflammation develops into atherosclerosis—deposits of cholesterol, fats and other substances that create plaque, clog arteries and ...

'Smart stent' detects narrowing of arteries

June 19, 2018
For every three individuals who have had a stent implanted to keep clogged arteries open and prevent a heart attack, at least one will experience restenosis—the renewed narrowing of the artery due to plaque buildup or scarring—which ...

Marriage may protect against heart disease / stroke and associated risk of death

June 18, 2018
Marriage may protect against the development of heart disease/stroke as well as influencing who is more likely to die of it, suggests a pooled analysis of the available data, published online in the journal Heart.

Deaths from cardiac arrest are misclassified, overestimated

June 18, 2018
Forty percent of deaths attributed to cardiac arrest are not sudden or unexpected, and nearly half of the remainder are not arrhythmic—the only situation in which CPR and defibrillators are effective—according to an analysis ...

Tick-borne meat sensitivity linked to heart disease

June 15, 2018
University of Virginia School of Medicine researchers have linked sensitivity to an allergen in red meat—a sensitivity spread by tick bites—with a buildup of fatty plaque in the arteries of the heart. This buildup may ...

The molecules that energize babies' hearts

June 14, 2018
A metabolic process that provides heart muscle with energy fails to mature in newborns with thickened heart walls, according to a Japan–Canada research team.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.